Keenova's XIAFLEX Shows Consistent Efficacy in Ventral Peyronie's Disease Curvature
Event summary
- Keenova Therapeutics presented final data on XIAFLEX's efficacy in treating ventral curvature in Peyronie's disease at the AUA annual meeting on May 15, 2026.
- The study confirmed consistent clinical effectiveness and safety outcomes for XIAFLEX in ventral curvature cases, aligning with results from other Peyronie's disease presentations.
- Jesse Mills, MD, Clinical Professor at UCLA, led the presentation, emphasizing the importance of non-surgical treatment options for Peyronie's disease.
The big picture
Keenova's updated data on XIAFLEX reinforces its role as a leading non-surgical treatment for Peyronie's disease, a condition affecting up to 1 in 10 men in the U.S. The findings could support broader clinical adoption and potentially open new market opportunities. The company's focus on rare and unaddressed conditions positions it well in the specialty therapeutics space, though competition and patient awareness remain key challenges.
What we're watching
- Therapeutic Expansion
- Whether Keenova can leverage these results to expand XIAFLEX's indications or seek regulatory approvals for broader Peyronie's disease applications.
- Market Penetration
- The pace at which Keenova can increase XIAFLEX adoption among urologists and patients, given the low diagnosis rates for Peyronie's disease.
- Competitive Dynamics
- How competing treatments or emerging therapies for Peyronie's disease may impact XIAFLEX's market position.